FO080APABETALONE, AN INHIBITOR OF BET PROTEINS, IMPROVES CARDIOVASCULAR RISK AND REDUCES ALKALINE PHOSPHATASE IN BOTH CVD PATIENTS AND PRIMARY HUMAN CELL CULTURE SYSTEMS
Bibliographic record
Abstract
INTRODUCTION: Apabetalone is an orally active inhibitor of bromodomain and extraterminal (BET) proteins - epigenetic readers modulating gene expression by bridging acetylated histones or transcription factors with transcriptional machinery. In phase 2 clinical trials, apabetalone reduced major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD), resulting in 44% relative risk reduction on top of standard of care. Chronic kidney disease (CKD) is frequently accompanied by cardiovascular complications, which remain resistant to current therapies. Elevated serum alkaline phosphatase (ALP) contributes to vascular calcification (VC) and endothelial dysfunction. Accordingly, serum ALP is emerging as an independent and novel predictor of MACE and of all-cause mortality. METHODS: Serum ALP levels were examined post-hoc in CVD patients receiving apabetalone in the 3 month (ASSERT) and 6 month (SUSTAIN & ASSURE) phase 2 trials, including a subset with impaired renal function (eGFR<60 mL/min/1.73m2). Effects of BET inhibitors (BETi) on expression of tissue-nonspecific ALP (TNAP; gene symbol ALPL) was determined in cultured primary human hepatocytes (PHH), the HepaRG cell line, primary human vascular smooth muscle cells (VSMCs) during trans-differentiation to calcifying cells, and vascular endothelial cells. ALP enzyme activity was measured in enzymatic assays. RESULTS: In phase 2 trials, baseline serum ALP independently predicted MACE (hazard ratio [HR] per SD 1.6, 95% CI 1.2-2.2, p=0.001). In ASSERT, apabetalone dose dependently reduced serum ALP (n=74-76/group; p<0.001 median change vs. placebo). Patients in phase 2 on apabetalone (n=553) had greater reductions in ALP than placebo (n=242; p<0.001). ALP reduction by apabetalone was associated with reduction in MACE (HR 0.58 per SD, 95% CI 0.44-0.77, p<0.001). In the subgroup with eGFR<60, patients on apabetalone (n=69) also had lower on-treatment serum ALP (p=0.008) vs. placebo (n=22). Liver-derived TNAP accounts for ≍50% of ALP enzyme activity in serum. In PHH & HepaRG cells, apabetalone suppressed ALPL expression by 60-80%. Vascular expression of ALPL also contributes to VC & cardiovascular risk. Compared to basal conditions, trans-differentiation of VSMCs to calcifying cells resulted in 2.5x increase in ALPL expression. Apabetalone or JQ1 (BETi with different chemical scaffolds) countered extracellular calcium deposition and suppressed ALPL gene expression, TNAP protein levels, and enzyme activity. Apabetalone downregulated ALPL expression in human aortic endothelial cells, umbilical vein endothelial cells, and brain microvascular endothelial cells by 50-70%. CONCLUSIONS: Apabetalone dose dependently lowers serum ALP in patients, which is associated with reduction in cardiovascular events. Decreased ALPL expression in cultured hepatocytes with apabetalone is consistent with reduced serum ALP in patients. In addition, apabetalone downregulates ALPL expression in vascular cell types including VSMCs and endothelial cells, while reducing VSMC calcification. Involvement of BET proteins in VSMC calcification is a novel discovery. Our data indicate apabetalone has potential to decrease progression of pathological VC and contribute to positive cardiovascular outcomes in CVD patients. The impact of apabetalone treatment on biomarkers, renal function, and CVD outcomes is being evaluated in the phase 3 BETonMACE trial (NCT02586155).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".